Efficacy of percutaneous ethanol injection versus radiofrequency ablation for single hepatocellular carcinoma no larger than 5 cm

Objective To compare the efficacy of percutaneous ethanol injection (PEI) and radiofrequency ablation (RFA) for patients with hepatocellular carcinoma (HCC) of no larger than 5 cm. Methods The data used in this study were retrieved from the SEER database. In total, 3510 patients diagnosed with HCC o...

Full description

Saved in:
Bibliographic Details
Published in:Journal of international medical research 2022-07, Vol.50 (7), p.3000605221111281-3000605221111281
Main Authors: Yang, Ping, Li, Ningjie
Format: Article
Language:English
Subjects:
Ablation
Liver cancer
Retrospective Clinical Research Report
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c509t-d073944ddcc0e6192707f9b4a279abbf7706cb0eb6b492c16f99c5e806e409333
cites cdi_FETCH-LOGICAL-c509t-d073944ddcc0e6192707f9b4a279abbf7706cb0eb6b492c16f99c5e806e409333
container_end_page 3000605221111281
container_issue 7
container_start_page 3000605221111281
container_title Journal of international medical research
container_volume 50
creator Yang, Ping
Li, Ningjie
description Objective To compare the efficacy of percutaneous ethanol injection (PEI) and radiofrequency ablation (RFA) for patients with hepatocellular carcinoma (HCC) of no larger than 5 cm. Methods The data used in this study were retrieved from the SEER database. In total, 3510 patients diagnosed with HCC of no larger than 5 cm who received PEI or RFA were included. Results The median overall survival (mOS) and median cancer-specific survival (mCSS) of RFA-treated patients were not significantly longer than those of PEI-treated patients either before or after propensity score matching (PSM). The subgroup analysis showed that patients with HCC of no larger than 2 cm, HCC of larger than 2 cm, American Joint Committee on Cancer (AJCC) stage I and II, and AJCC stage III and IV who received RFA had mOS and mCSS similar to those of patients who received PEI after PSM. Multivariable regression analysis showed that PEI did not increase the all-cause mortality risk or cancer-specific mortality risk after PSM. Conclusion RFA is still the better choice for patients with a single HCC of no more than 5 cm. However, PEI might be a good choice for these patients who cannot be treated with RFA.
doi_str_mv 10.1177/03000605221111281
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_2fa087298d7549bf8cd6421262f69ebb</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_03000605221111281</sage_id><doaj_id>oai_doaj_org_article_2fa087298d7549bf8cd6421262f69ebb</doaj_id><sourcerecordid>2697608692</sourcerecordid><originalsourceid>FETCH-LOGICAL-c509t-d073944ddcc0e6192707f9b4a279abbf7706cb0eb6b492c16f99c5e806e409333</originalsourceid><addsrcrecordid>eNp1ksFuFSEYhSdGY6_VB3BH4sbNVGAYGDYmpmm1SRM3uibA_MzlZgauMNOkOxNXvqZPUqbTaKqRDQnnnC9w-KvqNcFnhAjxDjcYY45bSklZtCNPqh1hoqlpEZ5Wu1WvV8NJ9SLnA8aM8pY-r06atuOEcrarflw45622tyg6dIRkl1kHiEtGMO91iCPy4QB29jGgG0i5CEn3ProE3xYIJafNqO9lFxPKPgwjoD0c9RwtjOMy6oSsTtaHOGkUIioHAyS00lH76_tPO72snjk9Znj1sJ9WXy8vvpx_qq8_f7w6_3Bd2xbLue6xaCRjfW8tBk4kFVg4aZimQmpjnBCYW4PBcMMktYQ7KW0LHebAsGya5rS62rh91Ad1TH7S6VZF7dX9QUyD0mn2dgRFncadoLLrRcukcZ3tOaOlMuq4BGMK6_3GOi5mgt5CmJMeH0EfK8Hv1RBvlGwIpqwrgLcPgBRLk3lWk89rY1v9ivLywJaV3yzWN39ZD3FJoVS1ugTHXfEWF9lcNsWcE7jflyFYreOi_hmXkjnbMlkP8If6_8AdqxPAuA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2697608692</pqid></control><display><type>article</type><title>Efficacy of percutaneous ethanol injection versus radiofrequency ablation for single hepatocellular carcinoma no larger than 5 cm</title><source>PubMed (Medline)</source><source>Sage Journals GOLD Open Access 2024</source><source>ProQuest - Publicly Available Content Database</source><creator>Yang, Ping ; Li, Ningjie</creator><creatorcontrib>Yang, Ping ; Li, Ningjie</creatorcontrib><description>Objective To compare the efficacy of percutaneous ethanol injection (PEI) and radiofrequency ablation (RFA) for patients with hepatocellular carcinoma (HCC) of no larger than 5 cm. Methods The data used in this study were retrieved from the SEER database. In total, 3510 patients diagnosed with HCC of no larger than 5 cm who received PEI or RFA were included. Results The median overall survival (mOS) and median cancer-specific survival (mCSS) of RFA-treated patients were not significantly longer than those of PEI-treated patients either before or after propensity score matching (PSM). The subgroup analysis showed that patients with HCC of no larger than 2 cm, HCC of larger than 2 cm, American Joint Committee on Cancer (AJCC) stage I and II, and AJCC stage III and IV who received RFA had mOS and mCSS similar to those of patients who received PEI after PSM. Multivariable regression analysis showed that PEI did not increase the all-cause mortality risk or cancer-specific mortality risk after PSM. Conclusion RFA is still the better choice for patients with a single HCC of no more than 5 cm. However, PEI might be a good choice for these patients who cannot be treated with RFA.</description><identifier>ISSN: 0300-0605</identifier><identifier>EISSN: 1473-2300</identifier><identifier>DOI: 10.1177/03000605221111281</identifier><identifier>PMID: 35861264</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Ablation ; Liver cancer ; Retrospective Clinical Research Report</subject><ispartof>Journal of international medical research, 2022-07, Vol.50 (7), p.3000605221111281-3000605221111281</ispartof><rights>The Author(s) 2022</rights><rights>The Author(s) 2022. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2022 2022 SAGE Publications</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c509t-d073944ddcc0e6192707f9b4a279abbf7706cb0eb6b492c16f99c5e806e409333</citedby><cites>FETCH-LOGICAL-c509t-d073944ddcc0e6192707f9b4a279abbf7706cb0eb6b492c16f99c5e806e409333</cites><orcidid>0000-0003-0998-6446</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310248/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2697608692?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,21966,25753,27853,27924,27925,37012,37013,44590,44945,45333,53791,53793</link.rule.ids></links><search><creatorcontrib>Yang, Ping</creatorcontrib><creatorcontrib>Li, Ningjie</creatorcontrib><title>Efficacy of percutaneous ethanol injection versus radiofrequency ablation for single hepatocellular carcinoma no larger than 5 cm</title><title>Journal of international medical research</title><description>Objective To compare the efficacy of percutaneous ethanol injection (PEI) and radiofrequency ablation (RFA) for patients with hepatocellular carcinoma (HCC) of no larger than 5 cm. Methods The data used in this study were retrieved from the SEER database. In total, 3510 patients diagnosed with HCC of no larger than 5 cm who received PEI or RFA were included. Results The median overall survival (mOS) and median cancer-specific survival (mCSS) of RFA-treated patients were not significantly longer than those of PEI-treated patients either before or after propensity score matching (PSM). The subgroup analysis showed that patients with HCC of no larger than 2 cm, HCC of larger than 2 cm, American Joint Committee on Cancer (AJCC) stage I and II, and AJCC stage III and IV who received RFA had mOS and mCSS similar to those of patients who received PEI after PSM. Multivariable regression analysis showed that PEI did not increase the all-cause mortality risk or cancer-specific mortality risk after PSM. Conclusion RFA is still the better choice for patients with a single HCC of no more than 5 cm. However, PEI might be a good choice for these patients who cannot be treated with RFA.</description><subject>Ablation</subject><subject>Liver cancer</subject><subject>Retrospective Clinical Research Report</subject><issn>0300-0605</issn><issn>1473-2300</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>AFRWT</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp1ksFuFSEYhSdGY6_VB3BH4sbNVGAYGDYmpmm1SRM3uibA_MzlZgauMNOkOxNXvqZPUqbTaKqRDQnnnC9w-KvqNcFnhAjxDjcYY45bSklZtCNPqh1hoqlpEZ5Wu1WvV8NJ9SLnA8aM8pY-r06atuOEcrarflw45622tyg6dIRkl1kHiEtGMO91iCPy4QB29jGgG0i5CEn3ProE3xYIJafNqO9lFxPKPgwjoD0c9RwtjOMy6oSsTtaHOGkUIioHAyS00lH76_tPO72snjk9Znj1sJ9WXy8vvpx_qq8_f7w6_3Bd2xbLue6xaCRjfW8tBk4kFVg4aZimQmpjnBCYW4PBcMMktYQ7KW0LHebAsGya5rS62rh91Ad1TH7S6VZF7dX9QUyD0mn2dgRFncadoLLrRcukcZ3tOaOlMuq4BGMK6_3GOi5mgt5CmJMeH0EfK8Hv1RBvlGwIpqwrgLcPgBRLk3lWk89rY1v9ivLywJaV3yzWN39ZD3FJoVS1ugTHXfEWF9lcNsWcE7jflyFYreOi_hmXkjnbMlkP8If6_8AdqxPAuA</recordid><startdate>20220701</startdate><enddate>20220701</enddate><creator>Yang, Ping</creator><creator>Li, Ningjie</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><general>SAGE Publishing</general><scope>AFRWT</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-0998-6446</orcidid></search><sort><creationdate>20220701</creationdate><title>Efficacy of percutaneous ethanol injection versus radiofrequency ablation for single hepatocellular carcinoma no larger than 5 cm</title><author>Yang, Ping ; Li, Ningjie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c509t-d073944ddcc0e6192707f9b4a279abbf7706cb0eb6b492c16f99c5e806e409333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Ablation</topic><topic>Liver cancer</topic><topic>Retrospective Clinical Research Report</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yang, Ping</creatorcontrib><creatorcontrib>Li, Ningjie</creatorcontrib><collection>Sage Journals GOLD Open Access 2024</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest - Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Journal of international medical research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yang, Ping</au><au>Li, Ningjie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of percutaneous ethanol injection versus radiofrequency ablation for single hepatocellular carcinoma no larger than 5 cm</atitle><jtitle>Journal of international medical research</jtitle><date>2022-07-01</date><risdate>2022</risdate><volume>50</volume><issue>7</issue><spage>3000605221111281</spage><epage>3000605221111281</epage><pages>3000605221111281-3000605221111281</pages><issn>0300-0605</issn><eissn>1473-2300</eissn><abstract>Objective To compare the efficacy of percutaneous ethanol injection (PEI) and radiofrequency ablation (RFA) for patients with hepatocellular carcinoma (HCC) of no larger than 5 cm. Methods The data used in this study were retrieved from the SEER database. In total, 3510 patients diagnosed with HCC of no larger than 5 cm who received PEI or RFA were included. Results The median overall survival (mOS) and median cancer-specific survival (mCSS) of RFA-treated patients were not significantly longer than those of PEI-treated patients either before or after propensity score matching (PSM). The subgroup analysis showed that patients with HCC of no larger than 2 cm, HCC of larger than 2 cm, American Joint Committee on Cancer (AJCC) stage I and II, and AJCC stage III and IV who received RFA had mOS and mCSS similar to those of patients who received PEI after PSM. Multivariable regression analysis showed that PEI did not increase the all-cause mortality risk or cancer-specific mortality risk after PSM. Conclusion RFA is still the better choice for patients with a single HCC of no more than 5 cm. However, PEI might be a good choice for these patients who cannot be treated with RFA.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>35861264</pmid><doi>10.1177/03000605221111281</doi><orcidid>https://orcid.org/0000-0003-0998-6446</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0300-0605
ispartof Journal of international medical research, 2022-07, Vol.50 (7), p.3000605221111281-3000605221111281
issn 0300-0605
1473-2300
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_2fa087298d7549bf8cd6421262f69ebb
source PubMed (Medline); Sage Journals GOLD Open Access 2024; ProQuest - Publicly Available Content Database
subjects Ablation
Liver cancer
Retrospective Clinical Research Report
title Efficacy of percutaneous ethanol injection versus radiofrequency ablation for single hepatocellular carcinoma no larger than 5 cm
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T08%3A45%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20percutaneous%20ethanol%20injection%20versus%20radiofrequency%20ablation%20for%20single%20hepatocellular%20carcinoma%20no%20larger%20than%205%E2%80%89cm&rft.jtitle=Journal%20of%20international%20medical%20research&rft.au=Yang,%20Ping&rft.date=2022-07-01&rft.volume=50&rft.issue=7&rft.spage=3000605221111281&rft.epage=3000605221111281&rft.pages=3000605221111281-3000605221111281&rft.issn=0300-0605&rft.eissn=1473-2300&rft_id=info:doi/10.1177/03000605221111281&rft_dat=%3Cproquest_doaj_%3E2697608692%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c509t-d073944ddcc0e6192707f9b4a279abbf7706cb0eb6b492c16f99c5e806e409333%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2697608692&rft_id=info:pmid/35861264&rft_sage_id=10.1177_03000605221111281&rfr_iscdi=true